ASAinesh Sewak

Ainesh Sewak

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ainesh Sewak has a total of 26 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Glial Fibrillary Acidic Protein (GFAP) as outcome in clinical trials in multiple sclerosis: current use and evidence-based sample size considerations

    by Louise Chaboud, Julian Hirt, Ainesh Sewak, Aleksandra Maleska Maceski, Jannis Müller, Tim Woelfle, Pascal Benkert, Sofia Sandgren, Maximilian Einsiedler, Jens Kuhle, et al.

  • Open Access

    Transformation Discriminant Analysis for Constructing Optimal Biomarker Combinations

    by Ainesh Sewak, Sandra Siegfried, Torsten Hothorn

    Accurate diagnostic tests are essential for effective screening and treatment. However, individual biomarkers often fail to provide sufficient diagnostic accuracy, as they typically capture only one aspect of the complex disease process. Combining multiple biomarkers, each capturing a distinct mechanism, can help construct more informative diagnostic tests. In practice, logistic regression is used as the default to combine biomarkers, but it can perform poorly when biomarker distributions exhibit skewness or differ across disease groups. Nonparametric methods provide more flexibility but generally require large sample sizes that are infrequently available in biomedical research. We propose a novel framework called transformation discriminant analysis which combines biomarkers through the likelihood ratio function to construct theoretically optimal diagnostic scores. Transformation discriminant analysis (TDA) balances between flexibility and efficiency. It can accommodate a wide range of distributional shapes and disease‐specific dependence structures while remaining fully parametric. This allows for likelihood inference and strong performance even in small‐sample settings. We evaluate TDA through simulations and benchmark its performance against commonly used methods. Finally, we illustrate its utility in constructing an optimal diagnostic test for hepatocellular carcinoma, a disease with no single ideal biomarker. An open‐source R implementation is provided for reproducibility and broader application.


  • Likelihood-based modeling of covariate-specific time-dependent receiver operating characteristic curves

    by Ainesh Sewak, Vanda Inácio, Joanne Wuu, Michael Benatar, Torsten Hothorn

    Identifying reliable biomarkers for predicting clinical events in longitudinal studies is important for accurate disease prognosis and for guiding development of new treatments. However, prognostic studies are often observational, making it difficult to account for patient heterogeneity. In amyotrophic lateral sclerosis (ALS), factors such as age, site of onset and genetic status influence both survival and biomarker levels, yet their impact on the prognostic accuracy of biomarkers over time remains unclear. While time-dependent receiver operating characteristic methods have been developed to handle censored time-to-event outcomes, most do not adjust for covariates. To address this, we propose the nonparanormal prognostic biomarker framework, which models the joint distribution of the biomarker and event time while accounting for covariates. This allows estimation of covariate-specific time-dependent receiver operating characteristic curves and related summary measures. We apply the NPB framework to evaluate serum neurofilament light as a prognostic biomarker in ALS, showing that its accuracy varies over time and with patient characteristics. By capturing these covariate-specific effects, the NPB framework supports more targeted risk stratification and can potentially improve the design of clinical trials for new ALS treatments.


  • Open Access

    Effects of Scaling Up Preexposure Prophylaxis on HIV Incidence in Men Who Have Sex with Men: An Application of Causal Inference Methodology

    by Ainesh Sewak, Sara Lodi, Xiaojuan Li, Di Shu, Lan Wen, Kenneth H. Mayer, Douglas Krakower, Jessica Young, Julia Marcus

    Background: Uptake of preexposure prophylaxis (PrEP) has been limited and inequitable. Although interventions to increase PrEP uptake are being evaluated in clinical trials among men who have sex with men (MSM), those trials cannot evaluate effects on the rare outcome of HIV incidence. Estimates from observational studies of the causal effects of PrEP uptake interventions on HIV incidence can inform decisions about intervention scale-up. Methods: We used electronic health record data from HIV-negative MSM accessing care at Fenway Health, a community health centre in Boston, Massachusetts, USA, from January 2012 through February 2018, with two years of follow-up. We considered stochastic interventions that increased the chance of initiating PrEP in several high-priority subgroups. We estimated the effects of these interventions on population-level HIV incidence using a novel inverse probability weighted estimator of the generalized g-formula, adjusting for baseline and time-varying confounders. Findings: Of 11,055 MSM, 2875 (26%) initiated PrEP during follow-up. We estimated an intervention that increased the probability of initiating PrEP by 10% in MSM tested for rectal STIs resulted in an increase in PrEP initiation among all MSM from the observed 26% to 48% (95% CI 47% to 49%), and a relative reduction in two-year HIV risk among all MSM of 27% (95% CI 8% to 43%). Interventions of the same strength among Black or Latino MSM increased PrEP initiation among all MSM from 26% to 35% (95% CI 34% to 36%), with a relative reduction in HIV risk of 22% (95% CI 6% to 36%). The intervention among Black or Latino MSM was the most efficient, yielding the largest reduction in population-level HIV risk relative to the increase in the total proportion initiating PrEP. Interpretation: Interventions that yield only modest increases in PrEP initiation in high-priority subgroups of MSM could meaningfully reduce HIV incidence in the overall population of MSM. Interventions tailored to Black and Latino MSM should be prioritized to maximize equity and impact. Funding: National Institute of Allergy and Infectious Diseases. Declaration of Interest: KHM has received unrestricted research grants from Gilead Sciences and served on a Scientific Advisory Board for them. DSK has conducted research at Fenway Health funded by grants from Merck and has received personal fees for developing medical education content for DKBMed, Virology Education and UpToDate, Inc. JLM previously consulted for Kaiser Permanente Northern California on a research grant from Gilead Sciences unrelated to the submitted work. All other authors declare no conflicts of interests. Ethical Approval: The institutional review boards at the Harvard Pilgrim Health Care Institute and Fenway Community Health determined this study to be exempt from review per 45 CFR Part 46 or 21 CFR Part 56, and that the information to be reviewed was fully de-identified per the HIPAA safe harbor standard, with no privacy review or approval of a HIPAA waiver required.